SCHEMBL7703565

SCHEMBL7703565

O=C(N[C@@H](Cc1ccccc1)C(=O)CNS(=O)(=O)c1ccccc1)c1ccc(NS(=O)(=O)c2ccc3ccccc3c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.51
LMNA P02545 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 1/20 0.51
GAA P10253 1/20 0.51
GPR27 Q9NS67 1/20 0.51
KAT6A Q92794 1/20 0.51
F2 P00734 1/20 0.48
PLAT P00750 2/20 0.48
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7706585 0.92 ALDH1A1 (0.53) CA2LMNASMN1; SMN2ALDH1A1GAA
SCHEMBL7692550 0.91 AKR1C3 (0.51) CA2LMNASMN1; SMN2ALDH1A1GPR27
SCHEMBL7700700 0.91 CA2 (0.52) CA2ALDH1A1KAT6AF2PLAT
SCHEMBL7695272 0.90 ALDH1A1 (0.52) CA2LMNASMN1; SMN2ALDH1A1GAA
SCHEMBL7689558 0.88 ALDH1A1 (0.55) CA2LMNASMN1; SMN2ALDH1A1GAA
SCHEMBL7682470 0.86 ALDH1A1 (0.51) CA2LMNASMN1; SMN2ALDH1A1GAA
SCHEMBL7701184 0.84 USP30 (0.49) CA2LMNASMN1; SMN2ALDH1A1HDAC3
SCHEMBL7694179 0.83 AKR1C3 (0.48) CA2LMNASMN1; SMN2ALDH1A1GAA
SCHEMBL7701695 0.83 CA2 (0.52) CA2GAAMMP9
SCHEMBL7704769 0.82 CA2 (0.52) CA2ALDH1A1KAT6AF2PLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6436925-B1 BETTER ABLE TO CROSS MEMBRANES; INHIBITORS OF CYSTEINE PROTEASES LIKE CALPAIN I AND II AND CATHEPSIN B AND L, CAN THUS BE USED TO CONTROL DISEASES ASSOCIATED WITH AN ELEVATED ACTIVITY OF CALPAIN ENZYMES OR CATHEPSIN ENZYMES ABBOTT LABORATORIES 2002-08-20 US disclosed